Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol

Czendlik, C.; Sioufi, A.; Preiswerk, G.; Howald, H.

doi:10.1007/s002280050318

Cited by 29 publications

(33 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this study are quantified by model approach and comparable with results obtained by Czendlik et al [13] who determined t max , k el and assessed AUC by using the linear trapezoidal method [13].…”

Section: Discussionsupporting

confidence: 84%

“…The study by Czendlik et al [13] reports that combined administration of atenolol and valsartan does not have any additional impact on the HR. These PD results show a reduction in SP that is 60% more efficient if atenolol is administered in combination with valsartan than atenolol alone (Table 7).…”

Section: Discussionmentioning

confidence: 97%

“…The study design was carried out as prior [13]. Briefl y, twelve healthy male adult volunteers (age: 23-46 years) participated in the study.…”

Section: Methodsmentioning

confidence: 99%

“…The HR and the blood pressure data were measured before the dosing, and 2, 4, 8, 12 and 24 h after dose administration with Dinamap monitor; model 1846 SX (Criticon, Tampa, Fl., USA). The blood pressure was measured by an automatic blood pressure monitor (Colin STBP-780 of Hayshi, Komaki City, Aichi, Japan) and the HR was detected by a telemetric system (Polar Electro, Finland) [13].…”

Section: Methodsmentioning

confidence: 99%

“…In comparison with these models, our study introduces a system approach to modeling of PK/PD interaction based on dynamic system theory [11,12] between antihypertensive drugs, their combination in relation with heart rate (HR), systolic blood pressure (SP) and diastolic blood pressure (DP), based on the data from study by Czendlik et al [13]. PD system analysis is based on modeling of PK and PK/ PD systems.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Quantifying pharmacodynamic interaction between atenolol and valsartan

et al. 2014

View full text Add to dashboard Cite

AbstractWe used mathematical modeling in order to determine the pharmacodynamic relationship between antihypertensive drugs atenolol and valsartan, by evaluating their effects on heart rate (HR), systolic blood pressure (SP) and diastolic blood pressure (DP). A group of twelve healthy male volunteers received a single oral dose of 100 mg of atenolol and 160 mg of valsartan, both separately and in combination. Pharmacokinetic (PK), pharmacokinetic/pharmacodynamic (PK/PD) and pharmacodynamic (PD) systems were proposed and PD model of atenolol and valsartan concentration-time profiles and PK/PD model of blood pressure and heart rate effects after administration of single doses of atenolol and valsartan and their combination were constructed. Parameters of PD system, such as gain and mean effect time, were obtained by analysis of PK and PK/PD systems. Modeling of PK and PK/PD systems and their analysis to obtain the PD results could considerably change the view o treatment of individual diseases in terms of greater knowledge of pharmacokinetics and pharmacodynamics of drugs.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 97%

“…The study design was carried out as prior [13]. Briefl y, twelve healthy male adult volunteers (age: 23-46 years) participated in the study.…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Quantifying pharmacodynamic interaction between atenolol and valsartan

et al. 2014

View full text Add to dashboard Cite

show abstract

Hydrophilic interaction liquid chromatographic tandem mass spectrometric determination of atenolol in human plasma

Francisco

et al. 2005

Biomedical Chromatography

View full text Add to dashboard Cite

A hydrophilic interaction liquid chromatographic method with tandem mass spectrometry for the determination of atenolol, a beta-blocking agent, in human plasma has been developed and validated over the curve range of 10--2000 ng/mL. The assay was based on protein precipitation followed by evaporation of the extraction solvent, reconstitution with acetonitrile, and chromatography on an Hypersil silica column (50 x 4.6 mm) using a low aqueous--high organic mobile phase. The mobile phase consists of 85% acetonitrile, 15% water, 0.5% acetic acid and 0.04% trifluoroacetic acid and runs isocratically at a flow rate of 2.0 mL/min. The column ef fluent was split so that 50% of it was transferred into the LC-MS/MS interface operated in positive electrospray ionization mode. The chromatographic run time was 2.0 min per injection. Atenolol and the internal standard, atenolol-d(7), showed a retention time of 1.0 min. The inter-day and intra-day precision and accuracy of the quality control samples were <5.3% relative standard deviation and <8.0% relative error, respectively. To explore the application of the current method for the analysis of other beta-blocking agents, propranolol and metoprolol were tested under the same chromatographic conditions with retention times of 0.68 and 0.75 min, respectively. The present method could be used for therapeutic drug monitoring, pharmacokinetic and drug--drug interaction studies of beta-blocking agents.

show abstract